Doctors, drugmakers, regulators and lobbyists pushed high doses of medications that may have been ineffective or at times even lethal on millions of anemic patients over two decades, making upward of $8 billion a year for two companies. “How did this happen?” asks Peter Whoriskey of The Washington Post.